Wingtech Pharma

Wingtech Pharmaceutical is a clinical-stage biotechnology company based in Suzhou, China, specializing in the discovery and development of innovative small molecule therapeutics for oncology and immunology. The company focuses on high-value, clinically validated targets where it can achieve superior selectivity and potency through its proprietary drug discovery platform. Its lead program, WT-2106, is a highly selective Janus kinase 1 (JAK1) inhibitor currently undergoing Phase 2 clinical trials for dermatological indications such as psoriasis and atopic dermatitis. Additionally, Wingtech is advancing WT-1108, a potent Hematopoietic progenitor kinase 1 (HPK1) inhibitor, into Phase 1 trials for the treatment of advanced solid tumors. By leveraging its expertise in medicinal chemistry and structural biology, Wingtech aims to deliver next-generation treatments that address significant unmet medical needs globally.